Sepracor ( SEPR) swung to a profit in the most recent second quarter, but the top line at the drugmaker came in lighter than analysts were expecting. For the quarter, consolidated revenue totaled $264.4 million. That was an increase from $185.1 million last year, but it missed Wall Street's consensus target of $279.4 million. Following the shortfall, Sepracor was selling off. In premarket trading Friday, the stock was down $3.14, or 6.6%, to $44.83. Net income was about $11.3 million, or 10 cents a share, compared with a loss of $7.4 million, or 7 cents a share, in the year-ago period. Results for the most recent second quarter included charges of $10.6 million, or 9 cents a share, for stock-based compensation. Analysts surveyed by Thomson Financial expected earnings of 9 cents a share from the Marlborough, Mass., maker of the insomnia drug Lunesta.